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DOI 10.1016/j.ccr.2012.01.004SUMMARYCurrent antiangiogenic agents used to treat cancer only partially inhibit neovascularization and cause normal
tissue toxicities, fueling the need to identify therapeutic agents that aremore selective for pathological angio-
genesis. Tumor endothelial marker 8 (TEM8), also known as anthrax toxin receptor 1 (ANTXR1), is a highly
conserved cell-surface protein overexpressed on tumor-infiltrating vasculature. Here we show that genetic
disruption of Tem8 results in impaired growth of human tumor xenografts of diverse origin including mela-
noma, breast, colon, and lung cancer. Furthermore, antibodies developed against the TEM8 extracellular
domain blocked anthrax intoxication, inhibited tumor-induced angiogenesis, displayed broad antitumor
activity, and augmented the activity of clinically approved anticancer agents without added toxicity. Thus,
TEM8 targeting may allow selective inhibition of pathological angiogenesis.INTRODUCTION and agents that target the VEGF/VEGFR2 axis have been clini-Solid tumors have an insidious ability to nourish their own expan-
sive growth by evoking the sprouting of new blood vessels, or
angiogenesis, from nearby vessels of neighboring nonmalignant
tissues. Upon vascularization, tumor blood vessels supply tumor
cells with vital oxygen and nutrients needed to support their
continued growth, and provide a key escape route for metas-
tasis. Due to their critical role in promoting tumor growth and
metastasis, tumor blood vessels have become a major target
of current anticancer therapy (Kerbel, 2008). Vascular endothe-
lial growth factor (VEGF) and its receptor, VEGFR2, represent
the most advanced targets of current antiangiogenic therapy,Significance
Inhibiting angiogenesis has become an important adjunct to
agents, including VEGF/VEGFR2 pathway inhibitors, disrupt n
increasing number of adverse side effects. TEM8 is an appe
because it is functionally required for optimal tumor angioge
and physiological angiogenesis. Function-blocking antibodies
ological angiogenesis and tumor growth and augmented the
VEGFR inhibitors. Thus, targeting TEM8 on tumor vasculatur
cancer and other diseases dependent on pathological angiog
212 Cancer Cell 21, 212–226, February 14, 2012 ª2012 Elsevier Inc.cally approved to treat patients with colon, lung, brain, and
kidney cancer (Brastianos and Batchelor, 2010; Kerbel, 2008).
Although therapies targeting VEGF/VEGFR2 have improved the
efficacy of current anticancer treatment strategies, angiogenesis
is seldom completely halted, and both angiogenesis and tumor
growth inevitably progress in the face of continued therapy.
Furthermore, in addition to its well-known role in physiological
angiogenesis of the adult, for example, during menstruation,
ovulation, and wound healing, VEGF is also widely expressed
in nonangiogenic normal adult tissues, where it plays critical
roles in normal adult physiology (Maharaj and D’Amore, 2007).
For example, it is required for normal kidney filtration (Ereminatraditional anticancer therapy, but current antiangiogenic
ormal physiological processes and are associated with an
aling target for selective inhibition of tumor angiogenesis
nesis and growth but dispensable for normal development
specific to the extracellular domain of TEM8 blocked path-
activity of various classes of anticancer agents, including
e may provide opportunities for the selective blockade of
enesis.
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2001), and maintaining functional hematopoietic, endocrine,
and skeletal systems (Sung et al., 2010). Given the pleiotropic
activities of the VEGF pathway, it is not surprising that anti-
VEGF/VEGFR2 therapies are associated with a number of toxic-
ities, such as hypertension, proteinuria, hypothyroidism, diar-
rhea, deep vein thromboses, fatigue, and surgical wound healing
complications (Verheul and Pinedo, 2007). VEGF-blocking
agents have also been associated with some rare, more serious,
side effects including life-threatening thromboembolic events
and severe bleeding complications (Chen and Cleck, 2009; Ver-
heul and Pinedo, 2007). Antiangiogenic therapies need to be
administered for months to years and may eventually prove
useful in long-term adjuvant therapy for the prevention of recur-
rent disease, raising further concerns about long-term toxicities.
Thus, drugs that can selectively target pathological host vascu-
lature with minimal side effects are urgently needed.
Tumor endothelial marker 8 (TEM8) is a highly conserved
single-pass cell-surface glycoprotein that was originally identi-
fied based on its overexpression in the endothelial cells (ECs)
that line the tumor vasculature of human colorectal cancer (St.
Croix et al., 2000). Although our understanding of its physiolog-
ical function is limited, TEM8 has been found to bind to collagens
and promotemigration of ECs in vitro (Nanda et al., 2004;Werner
et al., 2006). TEM8 was also identified as an anthrax toxin
receptor (ANTXR1) (Bradley et al., 2001), and it shares 58%
amino acid identity with CMG2, a second receptor for anthrax
toxin protein (ANTXR2) (Scobie et al., 2003). TEM8 is upregulated
on tumor vessels of various tumor types in both mice and hu-
mans (Carson-Walter et al., 2001; Fernando and Fletcher,
2009; Nanda et al., 2004), and in some tumors is also expressed
by the tumor cells themselves (Carson-Walter et al., 2001; Jinnin
et al., 2008; Yang et al., 2011b). TEM8 was unique among the
original TEMs identified in that it could not be detected in the
angiogenic corpus luteum of human ovaries (Nanda et al.,
2004; St. Croix et al., 2000), and developmental angiogenesis
and wound healing are unperturbed in Tem8 knockout (KO)
mice (Cullen et al., 2009). Indeed, aside frommisaligned incisors,
adult Tem8 KOmice are overtly normal in appearance. However,
murine B16 melanoma tumor growth was impaired in Tem8 KO
versus wild-type mice, demonstrating that host-derived TEM8
can promote tumor growth on an immunocompetent back-
ground (Cullen et al., 2009). Furthermore, previous studies
have shown that a soluble TEM8-Fc trap, TEM8 vaccines, or
sublethal doses of anthrax toxin can inhibit angiogenesis, slow
tumor growth, and prolong survival (Duan et al., 2007; Felicetti
et al., 2007; Liu et al., 2008; Rouleau et al., 2008; Ruan et al.,
2009; Yang et al., 2010). Taken together, these studies suggest
that TEM8may be required for tumor angiogenesis but not phys-
iological angiogenesis. Here we sought to develop anti-TEM8
antibodies that can block TEM8 function in an effort to selectively
block pathological angiogenesis.
RESULTS
TEM8 Functions in Pathological but Not Physiological
Angiogenesis
To obtain further evidence that TEM8 is selectively associated
with pathological angiogenesis, we compared the Tem8 expres-Csion pattern between tumor ECs and adult regenerating liver
ECs. Following 70% partial hepatectomy, the remaining liver
grows rapidly in a highly regulated angiogenesis-dependent
process (Drixler et al., 2002; Seaman et al., 2007). In this model,
quiescent ECs enter the cell cycle synchronously at around 24 hr
postsurgery and cease proliferation about 72 hr later. To
examine gene expression, we performed quantitative RT-PCR
(QPCR) on ECs purified from tumor xenografts derived from
DLD1, HCT116, or LS174T cells, or ECs isolated from quiescent
resting liver (0 hr) or regenerating liver taken at various postsur-
gical time points (6, 18, 48, 72, or 96 hr). Although markers of
proliferation, such as Ki67, protein regulator of cytokinesis 1
(Prc1), and thymidine kinase (TK) were highly induced in liver
ECs by 48 hr postpartial hepatectomy, Tem8 expression levels
remained baseline in regenerating liver ECs. In contrast, Tem8
was expressed 32- to 55-fold higher in each of the tumor EC frac-
tions compared to resting liver ECs (Figure 1A). The peak expres-
sion levels of the cell-cycle genes in regenerating liver ECs were
higher than that in tumor ECs, presumably because of the
synchronous nature of the proliferating liver EC population.
To investigate whether Tem8 is expressed by tumor-associ-
ated inflammatory cells, such as CD11b+ myeloid cells or other
bone marrow-derived cells that have been shown to promote
tumor angiogenesis and may be involved in the refractoriness
of tumors to VEGF inhibition (Du et al., 2008; Shojaei et al.,
2007), we examined its expression in CD45+ (pan hematopoi-
etic), CD11b+ (myeloid), and CD105+ (endothelial) cells isolated
from tumors. Tem8 was highly expressed only in the endothelial
fraction (Figure S1A available online). To determine potential
tumor microenvironmental factors that induce TEM8 expression
on tumor vasculature, we examined cultured human microvas-
cular endothelial cells (HMECs) in response to several condi-
tions. Neither coculture with tumor cells nor exposure to
hypoxia induced TEM8 (Figures S1B and S1C). However,
upon serum starvation, TEM8 levels steadily increased in these
cells, which normally express low endogenous TEM8 levels, re-
sulting in a 4-fold increase in TEM8 mRNA (Figure 1B) and
a 5-fold increase in TEM8 protein (Figure 1C) by day 10. In
contrast, TEM8 levels remained low in cells maintained in
complete medium, and the slight increase in TEM8 expression
noted at later time points (Figures 1B and 1C) may have been
due to rapid growth factor depletion caused by increasing cell
numbers (Figure 1D, top). The increase in TEM8 expression
upon growth factor starvation was not influenced by the amount
of cell-cell contact, based on comparisons of sparse versus
confluent cells wherein the cell numbers were held constant
but the surface area was altered (data not shown). Importantly,
TEM8 elevation in growth factor-starved cells could be inhibited
by fibroblast growth factor (FGF), VEGF, or serum treatment,
and the combination of all three resulted in the lowest TEM8
levels (Figures 1E and 1F; Figure S1D). Thus, TEM8 may be
part of a compensatory angiogenic or survival pathway that is
activated, at least in part, by insufficient local angiogenic growth
factors.
Host-Derived TEM8 Promotes the Growth of Human
Tumor Xenografts
To determine whether TEM8 could promote the growth of human
tumor xenografts, we generated Tem8 KO mice on anancer Cell 21, 212–226, February 14, 2012 ª2012 Elsevier Inc. 213
Figure 1. TEM8 Is Selectively Upregulated on Tumor Vasculature and Is Elevated in Cultured HMECs in Response to Growth Factor Depri-
vation
(A) QPCR was used to evaluate the expression of the indicated genes in ECs isolated from resting adult liver (0 hr), regenerating liver taken 6, 18, 48, 72, or 96 hr
following 70% partial hepatectomy, or DLD1, HCT116, or LS174T colon cancer xenografts.
(B) TEM8mRNA levels over the course of 10 days in HMECs grown in endothelial basal medium (EBM-2) or in complete medium (EBM-2 supplemented with FGF
[F], VEGF [V], and 5% fetal bovine serum [S]).
(C) TEM8 protein levels over the course of 10 days in HMECs grown in basal medium or in complete medium. The media are the same as in (B).
(D) The appearance of the cells used in (B) and (C) is shown. Note that HMECs became confluent by day 6 in complete medium but formed only small colonies by
day 10 in basal medium. The media are the same as in (B). The scale bar represents 100 mm.
(E and F) Effect of supplementation of basal growthmediumwith FGF, VEGF, or serum alone or all three together on the expression of TEM8 protein (E) andmRNA
(F) (*p < 0.05). Values in (A), (B), and (F) represent mean ± SD.
See also Figure S1.
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was inhibited in the Tem8 KO mice compared to WT littermate
controls when challenged with various tumor types including
melanoma (UACC and LOX), breast (MDA-MB-231), lung (NCI-
H460), and colon cancer (SW620, HCT116, and DLD1) (Figure 2).
The MDA-MB-231 breast tumors were grown orthotopically in
the mammary fat pad, whereas the melanoma and other tumor214 Cancer Cell 21, 212–226, February 14, 2012 ª2012 Elsevier Inc.types were grown subcutaneously. Tumor growth was consis-
tently slower in Tem8 KO versus WT mice, and SW620 tumors
required over 100 days to reach an average size of 800 mm3,
compared to only 35 days for WT littermates (Figure 2G). Thus,
host-derived TEM8 functions to promote the subcutaneous
and orthotopic growth of human tumor xenografts of diverse
origin.
Figure 2. The Growth of Human Tumor Xenografts Is Impaired in Tem8 KO Mice
Melanoma (A and B), breast (C), lung (D), and colon (E–G) cancer cell lines were injected into Tem8wild-type (blue) or knockout (red) mice and tumor volume was
monitored over time. The physical appearance of the resected UACC tumors is shown in (A). p values were calculated from the final tumor measurement (A–F) or
at day 41 (G), when the WT group reached its maximum size and had to be euthanized (Student’s t test). n = 7–15 mice/group. Values represent mean ± SE. The
scale bar represents 10 mm.
Cancer Cell
Anti-TEM8 Antibodies Inhibit Tumor GrowthDevelopment of Anti-TEM8 IgGs
Based on the functional importance of TEM8 in tumor growth
promotion, we sought to develop therapeutic anti-TEM8 anti-
bodies that could block TEM8 function in vivo. We had previ-
ously generated the SB series of anti-TEM8 antibodies (Nanda
et al., 2004). However, these antibodies were murine derived
and none of these could bind the predominant native form of
TEM8 on the cell surface (Nanda et al., 2004; Yang et al.,
2011b). To overcome these obstacles and circumvent potential
difficulties associated with breaking tolerance, we developed
another panel of fully human anti-TEM8 antibodies in vitro using
antibody phage display. The selection strategy, which involved
panning of Fab libraries on Tem8-transfected mammalian cells
and purified recombinant mammalian-derived TEM8-ED (extra-
cellular domain), resulted in the identification of five indepen-Cdent Fabs, L1, L2, L3, L5, and ID2. Each of the Fabs was found
to react with both mouse and human TEM8 in an ELISA and on
the surface of live TEM8-positive cells by immunofluorescence
and flow cytometry (Figures S2A–S2C). Although the physio-
logic ligand(s) of TEM8 in vivo is unclear, the TEM8 extracellular
region contains a single structural motif, that is, a von Wille-
brand factor type A (vWA) domain, where physiologic TEM8
ligand(s) is most likely to bind. vWA domains are found in
many extracellular eukaryotic proteins including integrins, and
are known to mediate adhesion to other proteins via metal-
ion-dependent adhesion sites. We reasoned that the protective
antigen (PA) subunit of anthrax toxin, which binds the exposed
vWA domain of TEM8 in a metal-ion-dependent manner, may
usurp the physiologic binding site of a natural ligand. Thus,
we screened the Fabs for the ability to block FITC-labeledancer Cell 21, 212–226, February 14, 2012 ª2012 Elsevier Inc. 215
Figure 3. L2 and L5 IgGs React Selectively with TEM8 and Block Binding and Toxicity of Anthrax Toxin Proteins
(A) L2 and L5 antibodies were used for flow cytometry staining of 293 cells stably transfected with mouse Tem8 (293-mTEM8) or a FLAG-tagged human TEM8
(293-Flag-hTEM8).
(B)L2andL5wereused forflowcytometrystainingofCHO/PR230 (CHO)cells (ananthrax toxin receptor-deficientcell line) thathadbeenstably transfectedwithhuman
TEM8 (CHO-TEM8) or human CMG2 (CHO-CMG2). FITC-labeled protective antigen (PA-FITC), which binds both TEM8 and CMG2, was used as a positive control.
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TEM8. Each of the Fabs blocked FITC-PA binding in a dose-
dependent manner (Figure S2D). Thus, we identified five human
anti-TEM8 Fabs that were positive in all screens and that con-
tained a unique variable domain.
Fabs have a relatively short half-life in vivo (several hours)
compared to full IgGs (several days). To enhance their stability
in vivo, two of the Fabs, L2 and L5, were selected for reformatting
to full IgG. For preclinical testing inmice, the constant domains of
mouse IgG2a (CH1, CH2, CH3, and CL) were fused to the human
variable domains (VH and VL) in order to minimize immunoge-
nicity, resulting in human-mouse chimeric antibodies. After refor-
matting, both L2 and L5 IgGs maintained their activity against
TEM8 in the same screens used to test the Fabs, and were
specific because they failed to react with mouse or human
CMG2, the closest homolog of TEM8 (Figures 3A–3D and data
not shown). Upon titration and comparison at nonsaturating
concentrations, L2 bound TEM8-expressing cells with 7-fold
higher affinity than L5 (EC50 0.4 and 2.8 nM, respectively; see
Figure S2E). Similarly, L2 was 4-fold more potent at blocking
the binding of FITC-labeled protective antigen and 9-fold
more potent at preventing cytotoxicity caused by anthrax lethal
toxin (Figures 3E–3G).Anti-TEM8 IgGs Inhibit Tumor Growth but Do Not Delay
Wound Healing
We tested the L2and L5antibodies for their activity against UACC,
HCT116, and DLD1 colon tumor xenografts in athymic nudemice.
In these studies, mice were treated with L2 or L5 once tumors
reachedanaverage sizeof 50mm3. For each tumor typeanalyzed,
a marked tumor growth inhibition was observed in each of the
treated groups compared to vehicle (PBS) alone (Figures 4A–4E).
Theantitumoractivitywascomparable to thatofanti-VEGFR2anti-
bodies (Figure 4C). When L2 and L5 were compared in a dose-
escalation study to determine the amount of antibody required
for optimal tumor growth inhibition, L2 showed superior activity.
A partial growth inhibition was observed when mice were given
2mg/kg of L2, whereasmaximum growth inhibition was observed
with 15 mg/kg (Figure 4E). L5, on the other hand, only showed
partial growth inhibition at 15 mg/kg, similar to that observed in
the 2mg/kg L2 treatment group, and in each tumor study required
30–40mg/kg to achieve its optimal biologic dose (OBD). Although
L5 required a higher dose than L2 to achievemaximumefficacy, at
their OBDs the two antibodies showed similar antitumor activity.
Taken together, these studies demonstrate a marked in vivo anti-
tumor activity of two independent anti-TEM8 antibodies. Because
the full IgG of L2 appeared more potent than L5 both in vitro and
in vivo, we focused on L2 for the remainder of our studies.
The aforementioned studies were conducted in immunocom-
promised mice. To determine whether L2 could suppress tumor(C) Western blot analysis was used to evaluate the expression of TEM8 and CM
(D) L2 antibodies were used for cell-surface immunofluorescence labeling of CH
(E) The ability of L2 and L5 antibodies to block binding of PA-FITC to CHO-TEM
(F) The viability of CHO and CHO-TEM8 cells was evaluated 48 hr posttreatmen
(G) The ability of L2 and L5 antibodies to protect cells from toxicity following treatm
was 1.9 and 16.6 nM, respectively. Values in (F) and (G) represent mean ± SE.
See also Figure S2.
Cgrowth in the presence of an intact immune system, we in-
jected murine B16 melanoma cells into syngeneic C57BL/6
mice and began treating mice with L2 at a tumor size of
50 mm3. The L2-treated group had a 60% reduction in tumor
growth by the end of the study (Figure 4F). Midway through
the therapeutic course, we also inflicted 6-mm-diameter
wounds into each of the tumor-bearing mice to determine
whether L2 treatment would interfere with wound healing.
Wound closure rates were not significantly altered by L2 (Fig-
ure 4G), despite its clear antitumor activity in the same mice.
Immunofluorescence staining for CD31 showed no alteration
in the amount of vasculature present within the healing wound
granulation tissue (Figure 4H). Matrigel-induced vascularization
was also unaffected by L2 treatment (Figure 4I). Thus, L2 anti-
bodies inhibited chronic pathological tumor growth while not
interfering with normal healing processes dependent on physi-
ological angiogenesis.
L2 Has No Detectable Toxicity
Two types of toxicology studies were conducted to determine
how well the L2 anti-TEM8 antibody was tolerated. The first
study involved dose escalation, wherein mice were administered
20, 50, or 100 mg/kg of L2 every other day for a total of three
treatments and then analyzed 24 hr later. All serum chemistry
and blood cell counts in the group treated with 100 mg/kg L2
were similar to that of the control group, and no dose-dependent
alterations were observed (Table 1; data not shown). Treated
mice consumed food and socialized similarly to control animals,
and both body and organ weights were unchanged (Figures S3A
and S3B). A comprehensive histopathologic analysis of 44
organs or tissues derived from 6 mice/group failed to reveal
any abnormalities (data not shown). The second toxicology
study involved treatment of mice with 20 mg/kg of L2 three times
per week for up to 6 weeks, followed by an analysis of the same
toxicology parameters. Again, no abnormalities were noted (Fig-
ure S3C; data not shown).
L2 Targets Tumor Vasculature In Vivo
To determine the specificity of L2 for TEM8 in vivo, we decided to
treat tumor-bearing Tem8 WT and KO mice with L2, reasoning
that L2 should only have activity against tumors in Tem8 WT
mice if the tumor cells employed do not themselves express
endogenous TEM8. TEM8 expression varied among cultured
tumor cell lines, among which DLD1 tumor cells expressed
undetectable TEM8 both in cell culture and following purification
from established tumors in vivo (Figures S4A and S4B). There-
fore, to test the specificity of the L2 antibody in vivo, Tem8 WT
and KO mice were challenged with DLD1 cells and treated with
L2 or control IgG (Figure 5A). As expected, tumors grew more
slowly in Tem8 KO compared to Tem8 WT mice treated withG2 in stably transfected CHO-TEM8 and CHO-CMG2 cells.
O and CHO-TEM8 cells.
8 cells was measured by flow cytometry.
t with lethal toxin.
ent with 1 mg of lethal toxin was evaluated. In this assay, the EC50 for L2 and L5
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Figure 4. Anti-TEM8 Antibodies Inhibit Tumor Growth but Do Not Delay Wound Healing
(A–F) Melanoma (A, B, and E: UACC; F: B16) or colon cancer (C: LS174T; D: HCT116) tumor cells were inoculated subcutaneously into athymic nude (UACC,
LS174T, HCT116) or C57BL/6 (B16) mice and tumor growth wasmonitored. Treatments with PBS (vehicle), anti-VEGFR2 antibodies, or anti-TEM8 antibodies (L2
or L5) were administered three times per week andwere initiated when tumors reached a size of 50mm3 (arrows). A Student’s t test was used to calculate p values
between the vehicle and L2 treatment groups at the final tumormeasurement. Tumors were excised at the end of the study to calculate final tumor weights (insets
in B–D). *p = 0.00005, **p = 0.002, ***p = 0.02.
(A) The physical appearance of the UACC melanoma tumors at the end of the study following surgical excision. The scale bar represents 10 mm.
(B) L2 inhibition of UACC melanoma tumor growth.
(C) L2 and DC101 (anti-VEGFR2) inhibition of LS174T tumor growth.
(D) L5 inhibition of HCT116 tumor growth.
(E) L2 and L5 dose-dependent inhibition of UACC tumor growth.
(F) L2 inhibition of B16 melanoma tumor growth.
Cancer Cell
Anti-TEM8 Antibodies Inhibit Tumor Growth
218 Cancer Cell 21, 212–226, February 14, 2012 ª2012 Elsevier Inc.





White blood cells (K/ml) 5.9 ± 2.5 6.3 ± 2.4
Red blood cells (M/ml) 9.5 ± 0.4 9.6 ± 0.4
Albumin (g/dl) 4.0 ± 0.4 3.9 ± 0.1
Alanine aminotransferase (U/l) 52.7 ± 10.1 51.9 ± 27.4
Total bilirubin (mg/dl) %0.2 %0.2
Creatine (mg/dl) %0.2 %0.2
Hemoglobin (g/dl) 13.9 ± 0.6 13.9 ± 0.4
Total protein (g/dl) 5.6 ± 0.2 5.7 ± 0.4
Blood urea nitrogen (mg/dl) 19.7 ± 2.0 17.5 ± 3.4
Selected Organ Weights (mg)
Brain 462 ± 19 465 ± 15
Heart 137 ± 15 155 ± 21
Kidney 312 ± 58 308 ± 63
Liver 1,173 ± 180 1,152 ± 271
Lung 153 ± 20 168 ± 34
Spleen 80 ± 13 83 ± 15
Represented toxicological data and organ weights from mice (n = 6/
group) dosed i.p. every second day with saline (control) or 100 mg/kg
anti-TEM8 mAb. Values are mean ± SD.
See also Figure S3.
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WT mice, tumor growth was inhibited relative to the IgG control
group but was indistinguishable from that in the Tem8 KO group.
Importantly, L2 treatment of Tem8 KO tumor-bearing mice did
not result in any further tumor growth inhibition. Taken together,
these results indicate that TEM8 is the sole target of L2 in vivo,
and supports the hypothesis that L2 is a function-blocking
monoclonal antibody.
The previously described expression of TEM8 in tumor endo-
thelium (Fernando and Fletcher, 2009; Nanda et al., 2004; St.
Croix et al., 2000) suggests that the target tissue of L2 in vivo
may be the tumor-associated vasculature. To assess this, we
performed CD31 vessel staining of the human DLD1 colon
cancer xenografts and found a reduced number of vessels in
tumors derived from Tem8 KO or L2-treated mice (Figure 5B).
Quantification of the number of CD31-positive ECs in tumors
using flow cytometry revealed significantly lower EC numbers
following both pharmacologic and genetic ablation of TEM8 (Fig-
ure 5C). We reasoned that TEM8 may promote proliferation of
tumor ECs, based on previous studies that showed a role for
CMG2 in promoting endothelial proliferation (Reeves et al.,
2010). However, endothelial proliferation in DLD1 tumors was
not altered in response to L2 treatment (Figure S4C), although
the number of apoptotic ECs was significantly increased (p <
0.02; Figure S4D).
To further assess the specificity of L2 in vivo, L2 was labeled
with FITC and then intravenously injected into DLD1 tumor-
bearing mice. Immunofluorescence analysis revealed localiza-
tion of TEM8 selectively in tumor-associated vasculature but
not in any of the normal control tissues analyzed including brain,
heart, intestine, liver, muscle, spleen, and stomach (Figure 5D).
Some tumor-associated perivascular stromal cells, including
pericytes based on their adjacent proximity to endothelium,
were also positive. However, stromal cell staining was confined
to the tumor region in Tem8 WT mice and was absent from the
tumors in Tem8 KO mice, confirming the specificity of antibody
staining (Figure 5E).
L2 Can Elicit NK-Mediated and Complement-Mediated
Cytotoxicity
We reasoned that the antitumor activity of L2 in vivo may involve
multiple mechanisms, and that antibody-dependent cellular
cytotoxicity (ADCC) and/or complement-dependent cytotoxicity
(CDC) could contribute to this activity. To determine whether
TEM8 could potentially function as a target of ADCC, we mixed
effector natural killer cells with TEM8-expressing 293 target cells
at various ratios and found that L2, but not control IgG, was able
to elicit cytotoxicity that was dependent on both the antibody
and effector cell concentration (Figures 5F and 5G). Similarly,
L2 elicited CDC in both an antibody- and complement-depen-
dent manner (Figures 5H and 5I). Although these in vitro studies
support a role for ADCC and CDC, further work is required to(G) Wound closure rates following treatment with L2 or vehicle (PBS) alone. In this
in (F).
(H) CD31 immunofluorescence staining of granulation tissue vasculature in co
experiment (n = 6 wounds/group).
(I) Matrigel plug vascularization was assessed following treatment with nonspecifi
per group. Values in (B)–(I) represent mean ± SE. The scale bars (H and I) repres
Cdetermine whether these mechanisms contribute to the anti-
tumor activity of L2 in vivo.
L2 Potentiates Tumoricidal Responses
The delayed tumor growth in Tem8 KO mice and the encour-
aging antitumor activity of L2 against relatively small established
50 mm3 tumors prompted us to explore the activity of L2 against
larger tumors. Importantly, even tumors that were 200 mm3 in
size prior to L2 treatment showed a significant response to the
antibody such that when the control tumors reached an average
size of 2,000 mm3, treated tumors had an average size of
1,288 mm3 (Figure 6A). However, because the L2-mediated
growth inhibition was less effective against relatively large
(200 mm3) preestablished tumors compared to small (50 mm3)
tumors (compare L2-treated group in Figure 6A with that in Fig-
ure 4B), we determined whether the combination of L2 with other
types of anticancer agents would result in enhanced antitumor
efficacy. When L2 treatment was combined with the anti-
VEGFR2 antibody DC101, which prevents VEGF from binding
VEGFR2, L2 significantly enhanced the activity of DC101 against
UACC melanoma (p < 0.05; Figure 6A). Furthermore, the combi-
nation of L2 with DMXAA (ASA404), a vascular targeting agent
that has shown promising activity in early clinical trials against
lung cancer (Baguley and McKeage, 2010), proved highlyexperiment, wounds were generated in the same tumor-bearingmice as shown
ntrol and L2-treated groups. Control mice received nonspecific IgG in this
c IgG or L2 anti-TEM8 antibodies. Vessel areas were calculated from six plugs
ent 100 mm.
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Figure 5. L2 Targets Tumor Vasculature In Vivo and Engages ADCC and CDC In Vitro
(A) Nonspecific antibodies (IgG control) or L2 anti-TEM8 antibodies were administered to Tem8 wild-type (T8-WT) or Tem8 knockout (T8-KO) mice at 20 mg/kg
mice three times per week beginning 1 day post-subcutaneous inoculation of TEM8-negative DLD1 tumor cells. At day 30 (asterisk), the tumors in the T8-WT +
IgG control groupwere significantly larger than those in each of the other three groups (p < 0.0001), but therewas no difference in tumor size between the T8-KO +
IgG, T8-WT + L2, and T8-KO + L2 groups (one-way ANOVA with Bonferroni posttest) (n = 12 mice/group).
(B) Immunofluorescence vessel staining of Tem8 WT and KO mice following treatment with L2 or IgG. Right: quantification of CD31-positive vessel area. p <
0.0001 between each of the groups and the IgG WT control group (one-way ANOVA). The scale bar represents 200 mm.
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Both L2 and DMXAA significantly delayed tumor growth, but
the combination was evenmore efficacious than either treatment
alone (p < 0.001; DMXAA + L2 versus DMXAA alone). Finally,
when L2 was combined with 5-fluorouracil (5FU) and irinotecan
(IRT), chemotherapeutic agents that are currently used to treat
patients with colorectal cancer, L2 significantly enhanced their
efficacy against HCT116 tumors (p < 0.0001, 5FU + L2 versus
5FU; p < 0.02, IRT + L2 versus IRT; Figures 6C and 6D). L2
also enhanced the efficacy of irinotecan against SW620 (p <
0.02, IRT + L2 versus IRT; Figure 6E), another colon cancer tumor
model, demonstrating the generality of this response. Combina-
tion of L2 with IRTwas highly efficacious, such that tumors in 5 of
11 mice in the HCT116 study and 4 of 11 mice in the SW620
study had completely regressed by 100 days postinoculation,
and thesemice remained tumor free for the duration of the study,
an additional 7 months (Figures 6D and 6E). No complete tumor
responses were observed in any of the monotherapy treatment
arms. To further assess the inhibitory activity of L2 + IRT
following long-term therapy, treatment was discontinued after
100 days, which resulted in rapid expansion of the remaining
tumors that had not completely regressed. Analysis of body
weights, food consumption, serum chemistry, and hematolog-
ical profiles in these combination drug trials failed to reveal
a change in toxicity caused by the addition of L2 to the chemo-
therapeutic agent (Figure 6F; Table S1). Taken together, these
studies demonstrate that L2 treatment can enhance the anti-
tumor responses of a wide variety of anticancer agents without
added toxicity.
L2 Binds Human Tumor Vasculature
To examine the specificity of L2 binding in human tumors, in situ
immunofluorescence staining with L2 was performed on colo-
rectal tumors or adjacent normal colonic mucosa derived from
six cases of late-stage colorectal cancer, four of which were
patientmatched. Although stainingwas undetectable in all cases
of normal colonic mucosa, in each of the tumor samples L2-FITC
strongly labeled the tumor stroma, including von Willebrand
factor (vWF)-positive ECs as well as some perivascular stromal
cells that, based on morphology, appeared to include pericytes
and possibly fibroblasts (Figure 7). Although the intensity of
stromal staining was variable in different regions of the tumor,
the staining was considered specific because it was completely
blocked by the addition of unlabeled L2 but not isotype-matched(C) Flow cytometry staining of dispersed tumor tissues was used to determine th
(WT-L2), IgG-treated tumors from Tem8 KOmice (KO-IgG), and IgG-treated tumo
for each of the groups, and the bar graph displays the average percentage of
significantly fewer cells than the WT-IgG group, as determined by a one-way AN
(D) L2 localization in vivo was assessed by immunofluorescence staining of vario
mice. An overlay of the L2 image (green) with the endothelial marker image (Mec
merge). The scale bar represents 50 mm.
(E) The specificity of L2-FITC for TEM8 in vivo was assessed by comparing the sta
bar represents 50 mm.
(F) NK-mediated toxicity against TEM8-expressing target cells was measured i
experiment was 25:1.
(G) The impact of increasing E:T cell ratios on L2-mediated ADCC was evaluated
(H) Complement-dependent cytotoxicity was assessed with varying amounts of
(I) To evaluate complement dependency, variable amounts of complement were
See also Figure S4.
Ccontrol IgG. Thus, in tumors derived from both patients and
mouse xenografts, TEM8 is found in tumor-associated vascula-
ture and tumor-associated perivascular stromal cells.
DISCUSSION
These studies demonstrate that TEM8 is critical for promoting
pathological angiogenesis evoked by a variety of tumor types,
and that antibody-mediated targeting of TEM8 provides
a rational strategy for combating cancer. Most angiogenesis
regulators that have been discovered to date cannot distin-
guish physiological and pathological angiogenesis. In immuno-
competent mice, L2 inhibited tumor growth but had no effect
on wound healing in the same mice, consistent with earlier
studies demonstrating no difference in wound healing between
Tem8 WT and KO mice (Cullen et al., 2009). TEM8 was also
dispensable for developmental angiogenesis and normal phys-
iological angiogenesis of the corpus luteum (Cullen et al., 2009;
Nanda et al., 2004; St. Croix et al., 2000). A function for TEM8 in
these normal physiological processes could potentially be
masked through compensation by another molecule. However,
CMG2 is the only other protein that shares significant amino
acid identity with TEM8 and, aside from misaligned incisors,
Cmg2/Tem8 double-mutant mice, like Tem8 KO mice, appear
to develop normally (Liu et al., 2009). These results support
the conclusion that physiological and pathological angiogen-
esis are distinct and that antibody-mediated targeting of
TEM8 can selectively inhibit pathological tumor growth while
sparing normal healing processes that also require
vascularization.
Based on our results, we propose that TEM8 overexpression
in tumor vasculature may be caused, at least in part, by local
decreases in the availability of stromal growth factors, such
as VEGF and FGF. At first, this might seem counterintuitive,
given the overall proangiogenic nature of tumors. However,
blood flow through the tortuous vessels in tumors is known to
be slow, erratic, and often static, which could contribute to
the rapid local depletion of angiogenic growth factors. Tumor
ECs may also have to compete for growth factors with tumor
cells that often express VEGF and/or FGF receptors themselves
and can sometimes utilize angiogenic growth factors for their
own growth (Dallas et al., 2007; Masood et al., 2001). Finally,
hypoxia, a well-known inducer of VEGF gene transcription,
may also lead to overexpression of the high-affinity VEGFR1e percentage of CD31-positive cells in L2-treated tumors from Tem8WT mice
rs from Tem8wild-type mice (WT-IgG). The dot plots show representative data
CD31-positive cells (n = 6/group). Both the WT-L2 and KO-IgG groups had
OVA.
us tissues following i.v. injection of FITC-labeled L2 into DLD1 tumor-bearing
a-32 or CD31, red) was used to assess colocalization with vasculature (yellow,
ining of tumor stroma from Tem8wild-type and Tem8 knockout mice. The scale
n the presence of L2 or control IgG. The effector:target (E:T) cell ratio in this
.
L2 or control IgG.
added to the CDC assay. Values in (A)–(C) and (F)–(I) represent mean ± SE.
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Figure 6. L2 Anti-TEM8 Antibodies Augment the Efficacy of Various Classes of Anticancer Agents
(A) UACC tumor growthwas compared following treatment with vehicle (PBS), nonspecific mouse IgG (20mg/kg), L2 anti-TEM8 (20mg/kg), anti-VEGFR2 (40mg/
kg), or a combination of L2 (20 mg/kg) and anti-VEGFR2 (40 mg/kg). Treatments were administered three times per week (arrows) beginning 15 days post-tumor
cell inoculation when tumors reached a size of 200 mm3.
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Figure 7. L2 Anti-TEM8 Antibodies Bind to the Vasculature of Human Colorectal Cancer
FITC-conjugated L2 (green) was used for immunofluorescence labeling of human colorectal tumors and normal colonic mucosa. The vasculature was costained
with antibodies against von Willebrand factor (red), a pan endothelial marker, and overlapping immunofluorescence is shown in the merged image (yellow). The
normal and tumor samples shownwere patient-matched and processed in parallel. To prevent nonspecific binding, immunofluorescence staining was performed
in the presence of a 50-fold excess of isotype-matched (human-mouse chimeric) control IgG that was generated against a foreign antigen (cyclosporine A). The
staining was abolished by blocking the samples with unlabeled L2 (bottom) prior to adding L2-FITC. The middle and bottom panels were taken from serial
sections. The scale bar represents 100 mm.
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can act as decoy receptors, limiting VEGF bioavailability (Lams-
zus et al., 2003; Yamaguchi et al., 2007; Yang et al., 2011a).(B) NCI-H460 tumor growth was compared following treatment with vehicle, L2 an
tumor inoculation when tumors reached an average size of 100mm3. In this experi
duration of the study, whereas DMXAA was administered at a high dose of 25 m
(C) HCT116 tumor growth was compared following treatment with vehicle, L2 ant
beginning 11 days post-tumor inoculation when tumors reached an average size
arrows), whereas 5FU was administered once a week for 3 weeks (black arrows
(D) HCT116 tumor growth was compared following treatment with vehicle, L2 anti
beginning 11 days post-tumor inoculation when tumors reached a size of 100mm3
100 days postinoculation. Tomaximize efficacy without excessive toxicity andmim
treatment per week for 3 weeks; black arrows) that were separated by a 2 week
conducted simultaneously and contain the same vehicle and L2 groups, which w
(E) SW620 tumor growth was compared following treatment with vehicle, L2 anti-
beginning 14 days post-tumor inoculation when tumors reached a size of 100 mm
above. IRT caused tumor regression in many of the treated mice. A decrease in tu
during the second cycle of IRT treatment. During the subsequent 2 week rest per
tumors in the combination group (IRT + L2) regressed again, whereas the larger tu
the error bars are shown in (D) and (E).
(F) Bodyweights inHCT116 tumor-bearingmice from the 5FUstudy (upper, corres
from the start of therapy until the tumors in the control groups reached their maxim
The SD ranged from 2% to 8%and error bars are omitted for clarity. The apparent
treatments (black arrows) were nonsignificant and were not altered by L2 treatme
CElevated TEM8 expression in tumor ECs in response to growth
factor deprivation and possibly other unidentified microenviron-
mental stressors may be part of a survival pathway that helpsti-TEM8, DMXAA, or a combination of L2 and DMXAA beginning 15 days post-
ment, L2 (20mg/kg) was administered three times per week (red arrows) for the
g/kg (black arrows), followed by 5 mg/kg/day the following 2 days.
i-TEM8 (20 mg/kg), 5-fluorouracil (100 mg/kg), or a combination of L2 and 5FU
of 100 mm3. In this experiment, L2 was administered three times per week (red
).
-TEM8 (20 mg/kg), irinotecan (80 mg/kg), or a combination of L2 and irinotecan
. In this experiment, L2was administered three times per week (red arrows) until
ic the clinical situation, IRT was administered in three cycles (where 1 cycle = 1
rest period to allow recovery. The HCT116 tumor studies in (C) and (D) were
ere duplicated for ease of comparison.
TEM8 (20 mg/kg), irinotecan (80 mg/kg), or a combination of L2 and irinotecan
3. The treatments in this study were the same as those described for HCT116
mor size caused by IRT is readily observed in both IRT arms (IRT and IRT + L2)
iod the tumors rapidly rebounded. Following the last cycle of IRT, many of the
mors in the control group did not respond. For ease of comparison, only half of
ponding toC) or the irinotecan study (lower, corresponding toD)weremonitored
um allowable size andmice had to be euthanized. Data represent mean values.
reduction inmean body weight observed following 5-fluorouracil and irinotecan
nt (red arrows). Values in (A)–(E) represent mean ± SE. See also Figure S5.
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provide a valuable tool for assessing the role of TEM8 in path-
ological angiogenesis. For most pharmacological angiogenesis
inhibitors, it is difficult to find animal models completely lacking
the drug target because the target proteins are usually required
for developmental angiogenesis, and temporally induced dele-
tion of a conditional ‘‘floxed’’ target gene in adult mice using
cre-lox technology is often incomplete. Importantly, by treating
Tem8 WT or KO mice with L2 anti-TEM8 antibody, we could
verify that TEM8 is the target of this antibody in vivo, and that
L2 treatment inhibits tumor growth to a level similar to complete
genetic ablation. Further evidence for antibody specificity was
obtained using FITC-labeled L2 that selectively reacted with
the tumor vessels in Tem8 WT but not KO mice.
Multiple mechanisms could potentially contribute to the anti-
tumor activity of L2 in vivo, but so far the evidence suggests
that the antibodies work primarily by blocking TEM8 function
and that ADCC and CDC may play a more limited role. The
extent of tumor growth delay observed in Tem8 KO mice was
found to vary depending on the tumor type employed, but
the same tumor-type-dependent responses were observed
following L2 blockade. For example, UACC tumors consistently
displayed the most pronounced growth delay in Tem8 KO
versus WT mice, and were also the most responsive to L2.
Indeed, the tumor growth patterns observed in Tem8 KO
mice were found to be indistinguishable from those observed
in the L2-treated Tem8 WT mice, provided that L2 treatment
began immediately following tumor cell inoculation (for
example, see Figure 5A). It is currently unclear why some tumor
types rely more on host-derived TEM8 than others, but the
degree of TEM8 dependence does not appear to correlate
with the tumor cells’ ability to evoke TEM8 expression in nearby
tumor-associated ECs. For example, in Tem8 WT mice, tumor
ECs isolated from LLC tumors expressed four times more
Tem8 than those isolated from B16 tumors, yet comparisons
of tumor growth in Tem8 WT and KO mice revealed that B16
tumors are more dependent on host-derived TEM8 than LLC
cells (Cullen et al., 2009). We expect that if ADCC and CDC
were the major mechanisms governing tumor responses in vivo,
then tumor responsiveness would have correlated with TEM8
expression levels in tumor ECs, because ADCC and CDC
both depend on target antigen expression levels. Therefore,
further studies are required to establish whether ADCC and
CDC contribute significantly to L2’s activity in vivo. Neverthe-
less, affinity maturation of the variable domain and modifica-
tions to the Fc domain that enhance ADCC and CDC activity
(Natsume et al., 2009) could lead to further enhancement of
antitumor efficacy.
Although anti-TEM8 antibodies inhibited tumor growth as
a monotherapy, based on our results we predict that TEM8 anti-
bodies may be most useful in combination with other agents.
TEM8 antibodies were completely nontoxic and displayed effi-
cacy when combined with various classes of anticancer agents.
That anti-TEM8 antibodies augment the activity of VEGFR2-
neutralizing antibodies suggests that signaling pathways
involving TEM8 may be responsible, at least in part, for angio-
genesis that persists following VEGF/VEGFR2 inhibition.
Although human-mouse chimeric antibodies were employed in
the preclinical studies described here, reengineering of the Fc224 Cancer Cell 21, 212–226, February 14, 2012 ª2012 Elsevier Inc.domain can be used to make the IgG fully human for future clin-
ical development.
In summary, we report the development of anti-TEM8 anti-
bodies that retard tumor growth by inhibiting tumor angiogen-
esis. Anti-TEM8 antibodies were nontoxic and maintained effi-
cacy in combination with various classes of anticancer agents.
Thus, anti-TEM8 antibodies provide a rationally designed tool
for selectively inhibiting pathological angiogenesis with impor-
tant ramifications for the management of angiogenesis-depen-
dent diseases.
EXPERIMENTAL PROCEDURES
Antibody Production and Purification
In vitro selection of the Morphosys HuCAL Gold phage library involved two
rounds of sequential panning on biotinylated, purified recombinant
TEM8(ED)-Fc fusion proteins, prepared as described in Supplemental Experi-
mental Procedures, andone roundofpanningonHEK293cells transfectedwith
human TEM8 (293/Flag-hTEM8). DNA inserts for the Fab heavy and light chains
were subcloned and expressed, and bivalent Fabs were evaluated for TEM8
binding by ELISA (see Supplemental Experimental Procedures). Two of the
TEM8-binding clones (L2 and L5) were reformatted to generate mouse-human
chimeric full IgGs. Anti-TEM8 antibodies were collected from HEK293T culture
supernatants and purified by protein A and size exclusion chromatography.
Western Blotting
Western blotting was performed using antibodies against TEM8 (clone SB5;
Nanda et al., 2004), CMG2 (a kind gift from Stephen Leppla), actin (Chemicon),
or HIF-1a (Novus Biologicals) as previously described (Cullen et al., 2011).
Animal and Tumor Studies
To derive Tem8KOmice on an immunodeficient background, Tem8KOmice on
aC57BL/6background (Cullenetal., 2009)werecrossedwithathymicNCr-nu/nu
mice, and only Tem8WT and KO littermates derived from Tem8 heterozygous
intercrosses were used for comparison. Tumors were measured with a caliper,
and tumor volumes were calculated using the formula length 3 width2 3 0.5
and presented as the mean ± SE. All animal studies were carried out in accor-
dance with protocols approved by the NCI Animal Care and Use Committee.
Immunofluorescence
For in vivo target identification, FITC-labeled L2 was coinjected with nonspe-
cific mouse IgG intraperitoneally into DLD1 tumor-bearing Tem8 WT and KO
mice. Frozen sections were labeled with rat anti-PV-1 (Meca-32) or rat anti-
CD31 (BD Pharmingen) antibodies. For immunofluorescence staining of
human normal colonic mucosa or colorectal cancer, frozen tissue sections
were blocked with nonspecific mouse-human chimeric IgG antibodies (mouse
Fc/human Fab) generated against cyclosporine A and detected with L2-
labeled FITC. The anonymized human colon tissue samples were obtained
from the Cooperative Human Tissue Network with approval from the NIH
Office of Human Subject Research. Further details regarding the immunofluo-
rescence staining can be found in Supplemental Experimental Procedures.
Statistical Analysis
A Student’s t test was used to calculate differences in tumor volumes or
weights between two groups (for example, Tem8 WT and KO mice) at the
time when the WT (or control) group reached its maximum size and had to
be euthanized. For comparisons between multiple tumor groups, a one-way
ANOVA was used with a Bonferroni posttest. A one-way ANOVA was used
for comparisons of microvascular densities and the fraction of CD31-positive
cells by flow cytometry. p values < 0.05 were considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2012.01.004.
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